Back to top
more

Electromed (ELMD)

(Delayed Data from AMEX)

$16.73 USD

16.73
20,645

+0.34 (2.07%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $16.38 -0.35 (-2.09%) 6:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Electromed, Inc. (ELMD) Upgraded to Buy: Here's What You Should Know

Electromed, Inc. (ELMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bears are Losing Control Over Electromed, Inc. (ELMD), Here's Why It's a 'Buy' Now

Electromed, Inc. (ELMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Electromed, Inc. (ELMD) Lags Q1 Earnings Estimates

Electromed, Inc. (ELMD) delivered earnings and revenue surprises of -16.67% and 11.12%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Electromed, Inc. (ELMD) Reports Next Week: What Awaits?

Electromed, Inc. (ELMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Electromed, Inc. (ELMD) Q4 Earnings Meet Estimates

Electromed, Inc. (ELMD) delivered earnings and revenue surprises of 0.00% and 1.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Electromed, Inc. (ELMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Electromed, Inc. (ELMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alcon (ALC) to Report Q2 Earnings: What's in the Cards?

Continued strength in the Surgical segment and new launches under Vision Care segment are likely to have driven growth in the second quarter for Alcon (ALC).

New Strong Sell Stocks for June 3rd

ADSK, BNR, NET, ELMD, and POLY have been added to the Zacks Rank #5 (Strong Sell) List on June 3, 2021

New Strong Sell Stocks for May 13th

PRTS, CIGI, ELMD, LLY, and TTWO have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2021

Earnings Preview: Electromed, Inc. (ELMD) Q3 Earnings Expected to Decline

Electromed, Inc. (ELMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Varian Medical (VAR) Hits 52-Week High: What's Driving It?

Varian Medical (VAR) is optimistic about its prospective acquisitions and strength in Proton Therapy segment.

Electromed, Inc. (ELMD) Q2 Earnings and Revenues Top Estimates

Electromed, Inc. (ELMD) delivered earnings and revenue surprises of 225.00% and 15.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Electromed, Inc. (ELMD) Q2 Earnings Expected to Decline

Electromed, Inc. (ELMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Electromed Enters Oversold Territory

Electromed has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Electromed Enters Oversold Territory

Electromed has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

The Zacks Analyst Blog Highlights: TVTY, NXGN, ELMD and FMS

The Zacks Analyst Blog Highlights: TVTY, NXGN, ELMD and FMS

Debanjana Dey headshot

4 MedTech Growth Stocks With Strong ROE to Buy Amid Coronavirus

Here are some MedTech growth stocks which might be solid investment options for profit-maximization amid the coronavirus-led market mayhem.

Zacks.com featured highlights include: Vista Outdoor, 21Vianet, Electromed and GAIN Capital

Zacks.com featured highlights include: Vista Outdoor, 21Vianet, Electromed and GAIN Capital

Nitish Marwah headshot

4 Breakout Stocks for Explosive Returns

In order to select the right breakout stock one has to first calculate its support and resistance level.

Sejuti Banerjea headshot

5 Themes (& Picks) for Coronavirus Investing

Coronavirus is going to be around for a while, so let's use it to define our investment strategies.

Zacks.com featured highlights include: Electromed, NovaGold Resources, FTI Consulting, Eli Lilly and Masimo

Zacks.com featured highlights include: Electromed, NovaGold Resources, FTI Consulting, Eli Lilly and Masimo

Nalak Das headshot

5 Stocks With Recent Price Strength Amid Coronavirus Logjam

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

4 Stocks Trading Near 52-Week High That Can Scale Higher

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Benjamin Rains headshot

Why Soaring Health Industry Stock DexCom is a Strong Buy Right Now

DexCom shares have soared 45% since March 18. The connected glucose monitoring systems firm is also expected to continue to grow and DXCM stock might be somewhat immune to the current coronavirus economic uncertainty...

Nalak Das headshot

5 Top Low-Beta Stocks Surged in March Defying Coronavirus

The global financial markets are currently witnessing one of the worst periods since the Great Depression due to the coronavirus-led crisis.